Contact us Demo our platform

Cannabivarin

Cannabivarin

Linear Formula

C19H22O2

Synonyms

Cannabivarol

Share this metabolite

What is Cannabivarin (CBV)?

Cannabivarin (CBV), also known as cannabivarol, is a non-psychoactive cannabinoid and does not produce the psychophysiological effects elicited by its more well-known relative, tetrahydrocannabinol (THC)1, the primary psychoactive cannabinoid extracted from the cannabis plant (i.e., marijuana plant) responsible for euphoric side effects. A lesser-known cannabinoid, CBV is an analog of cannabinol and an oxidation product of tetrahydrocannabivarin2. It has a low binding affinity to cannabinoid receptors CB1 and CB2. CBV is a natural product detected in minor amounts in the hemp plant Cannabis sativa.

Research has shown that another non-psychoactive cannabinoid, cannabidiol (CBD), has several potential therapeutic benefits for a range of diseases, including multiple sclerosis, neuropathic pain, and mood disorders. However, there is limited research on the mechanisms and kinetics involved with CBV metabolism and its impact on the endocannabinoid system. Therefore, this compound’s physiological and neurological effects on the human body — and, therefore, its pharmacological potential — are relatively unknown.

Cannabivarin Figure

(Figure from Sampson 2021)

Cannabivarin and Drug Development

While the potential benefits of CBV are still under investigation, preliminary research has demonstrated promise for CBV as a component in drug development for treating bladder cancer and SARs-CoV-2.

SARs-CoV-2, characterized as a severe acute respiratory syndrome, is partly mediated by the angiotensin-converting enzyme 2 (ACE2) receptor, an essential component of the renin-angiotensin-aldosterone system. One report examined the active components of Cannabis sativa and their interaction with ACE2 receptors. Their results demonstrated that several cannabinoids bind to ACE2, including CBV3.

Cannflavin A is another compound found in Cannabis sativa, and research has begun to demonstrate its potential in inducing cytotoxicity to human bladder carcinoma cells. Interestingly, one study showed that Cannflavin A has synergistic properties with other chemotherapeutic agents and a number of other cannabinoids, including CBV4.

As researchers continue to unravel the pharmacological and physiological mechanisms of CBV, more research, both in vitro and in vivo, is required to assess its potential use — as well as that of many other cannabinoids — in drug development.

Metabolon’s Cannabinoids Targeted Panel

Metabolon’s Cannabinoids Targeted Panel provides precise and accurate measurements of nine of the most common cannabinoids, including cannabivarin. Metabolon has developed a suite of tools built from thousands of metabolomics studies to help you maximize the discovery potential of your research projects. Contact us today to learn more about our Cannabinoid Targeted Panel.

References

  1. National Library of Medicine, National Center for Biotechnology Information. PubChem Compound Summary, Cannabivarin (CID 622545).
  2. Bailey K and Gagne D. Distinction of synthetic cannabidiol, cannabichromene, and cannabivarin by GLC using on-column methylation. J Pharm Sci 1975;64(10):1719–1720.
  3. El Ouafi Z, Rhalem W, Habib N et al. Molecular Modeling Targeting the ACE2 Receptor with Cannabis sativa’s Active Ingredients for Antiviral Drug Discovery against SARS-CoV-2 Infections. Bioinform Biol Insights 2022;16:11779322221145380.
  4. Tomko AM, Whynot EG, and Dupre, DJ. Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer. J Cannabis Res 2022;4(1):41.
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.